Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Rheumatoid Arthritis
What is your approach to a patient with rheumatoid arthritis and moderate disease activity on 25 mg of PO methotrexate?
Do you switch to SQ MTX, or is it best to add tx, such as a TNFi?
Answer from: at Community Practice
Switching to sub cu may work for low disease activity, but not moderate.
Sign in or Register to read more
10978
Related Questions
Do you consider new onset autoimmune disease (e.g. seronegative rheumatoid arthritis) a few months after completing immunotherapy for cancer to be an immune-related adverse effect to the immunotherapy?
How do you approach monitoring when using combination JAK inhibitors and methotrexate in RA?
Does the presence of bronchiectasis change your approach to a patient with otherwise well-controlled patient with RA?
What is your treatment approach for a young female who has an idiopathic small right elbow effusion with synovial thickening that has resulted in limitation in her range of motion?
Would you continue Jak inhibitor therapy in a patient with long standing, previously refractory RA in their 60s who was found to have stenosis of the left common femoral artery and no other history of arteriosclerotic disease?
What is your approach to work up for patients referred for early onset osteoarthritis?
Do you have experience combining tocilizumab with mycophenolate in patients with scleroderma lung disease and inflammatory arthritis?
How do you approach venous insufficiency management in patients on Jak inhibitors?
How would you manage a patient with progressive/refractory molluscum contagiosum who is well controlled on methotrexate for seropositive rheumatoid arthritis?
How would you approach management of a patient who develops squamous cell skin cancer while on abatacept?